Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
ARQT Stock Chart & Stats
$21.83
-$0.25(-1.59%)
At close: 4:00 PM EST
$21.83
-$0.25(-1.59%)
Day’s Range― - ―
52-Week Range$11.86 - $31.77
Previous CloseN/A
Volume446.87K
Average Volume (3M)1.39M
Market Cap
$2.76B
Enterprise Value$2.67B
Total Cash (Recent Filing)$220.98M
Total Debt (Recent Filing)$6.27M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
May 19, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding124,033,380
10 Day Avg. Volume1,473,860
30 Day Avg. Volume1,389,409
Financial Highlights & Ratios
PEG Ratio2.58
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.10
Enterprise Value/Gross Profit7.87
Enterprise Value/Ebitda1.01K
Forecast
1Y Price Target
$34.33Price Target Upside57.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.34
Revenue Forecast (FY)$495.76M
Bulls Say, Bears Say
Bulls Say
Commercial Momentum And GuidanceNet product revenue guidance was raised after Zoryve prescription volumes and realized pricing outpaced expectations, signaling stronger commercial momentum that can lift valuation.
Pipeline And Label ExpansionAdvancing clinical programs into new indications and pursuing pediatric label approvals could substantially enlarge the addressable market for Zoryve and support long‑term revenue growth.
Sales Force Expansion And TargetingPlanned expansion of the dermatology sales team and a new commercial push toward primary care doctors and pediatricians is intended to increase call frequency and broaden Zoryve adoption.
Bears Say
Competitive Pressure And Displacement RiskA crowded dermatology market and the potential rise of targeted oral therapies increase the chance of pricing pressure or market share loss for Zoryve.
Near‑term Revenue HeadwindsManagement expects a pronounced revenue step‑down driven by deductible resets, higher copay use, channel inventory unwind, and weather disruption, which can pressure short‑term sales.
Product Concentration RiskHeavy reliance on a single commercial product creates significant downside risk if Zoryve faces safety, access, or competitive setbacks that shrink revenue.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $11.86 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $2.76B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is May 19, 2026 which is in 55 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Feb 25, 2026. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.092 by $0.038.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is -0.05.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 124,033,380 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of $0.13 in its last earnings report, beating expectations of $0.092. Following the earnings report the stock price went up 5.776%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.33 (57.26% Upside)
$34.33 (57.26% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.25%
12-Months-Change
Fundamentals
Return on Equity
-10.26%
Trailing 12-Months
Asset Growth
24.10%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT Company Deck
ARQT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial picture: very strong top-line growth (123% YoY for FY2025), record Q4 results, robust prescription momentum, expanded approvals and encouraging pediatric Phase II data, improved profitability and positive cash flow, and raised 2026 guidance. Offsetting risks include higher SG&A/R&D investment leading to elevated operating expenses, quarter-to-quarter seasonal and gross-to-net variability (notably a Q1 headwind), limited Medicare Part D coverage with non-preferred tier placement, and execution/timing risk as the company scales its sales force and primary care efforts. Overall, the company appears to be scaling successfully while mindful of near-term investment-driven expense and access nuances.View all ARQT earnings summariesARQT Stock 12 Month Forecast
Average Price Target
$34.33
▲(57.26% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.41% Insiders
16.36% Mutual Funds
52.25% Other Institutional Investors
8.51% Public Companies and Individual Investors